Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ECUR-506
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ECUR-506, incorporates an ARCUS nuclease vector targeting gene editing in the well-characterized PCSK9 gene locus and a donor vector that inserts the desired functional OTC gene for the treatment of Ornit...
Brand Name : ECUR-506
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
May 07, 2024
Lead Product(s) : ECUR-506
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ECUR-506
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ECUR-506, incorporates an ARCUS nuclease vector targeting gene editing in the well-characterized PCSK9 gene locus and a donor vector that inserts the desired functional OTC gene for the treatment of neona...
Brand Name : ECUR-506
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
April 04, 2024
Lead Product(s) : ECUR-506
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ECUR-506
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Recipient : Precision BioSciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Arcus is a platform designed to develop in vivo gene editing therapies, including gene insertion, excision, and elimination. It has received TGA approval for initiation of Phase 1/2 trial evaluating ECUR-...
Brand Name : ECUR-506
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
December 13, 2023
Lead Product(s) : ECUR-506
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Recipient : Precision BioSciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : GTP-506A,GTP-506D
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GTP-506 comprises two vectors, an ARCUS® nuclease vector (GTP-506A) targeting gene editing in the well-characterized PCSK9 gene locus and a therapeutic donor vector that inserts the OTC gene.
Brand Name : GTP-506
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
September 06, 2022
Lead Product(s) : GTP-506A,GTP-506D
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : GTP-506A,GTP-506D
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GTP-506, a potential single-dose gene editing therapy designed to restore metabolic function in patients suffering with OTC deficiency, a rare urea cycle disorder.
Brand Name : GTP-506
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
August 23, 2022
Lead Product(s) : GTP-506A,GTP-506D
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Endonuclease-based Gene Therapy
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Sponsor : Versant Ventures
Deal Size : $50.0 million
Deal Type : Series A Financing
Details : The funds will be used to advance iECURE’s pipeline of up to 13 programs rely on the use of an endonuclease-based gene editing technology delivered via AAV.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 09, 2021
Lead Product(s) : Endonuclease-based Gene Therapy
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Sponsor : Versant Ventures
Deal Size : $50.0 million
Deal Type : Series A Financing
Lead Product(s) : PBGENE-PCSK9
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Recipient : Precision BioSciences
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the agreement, iECURE plans to file a clinical trial application to advance the PBGENE-PCSK9 clinical candidate through Phase 1 clinical studies for the treatment of familial hyperchole...
Brand Name : PBGENE-PCSK9
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 09, 2021
Lead Product(s) : PBGENE-PCSK9
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Recipient : Precision BioSciences
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?